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Abstract  31 
Background:  Observational studies suggest that early regular ingestion of allergenic foods 32 
may reduce the risk of food allergy.  33 
Objective:  To determine if early regular oral egg exposure will reduce subsequent IgE-34 
mediated egg allergy in infants with moderate to severe eczema.  35 
Methods:  In a double-blinded randomized controlled trial, infants were allocated to one 36 
teaspoon of pasteurized raw whole egg powder (n=49) or rice powder (n=37) daily from 4-8-37 
months of age.  Cooked egg was introduced to both groups after an observed feed at 8-38 
months.  The primary outcome was IgE-mediated egg allergy at 12-months defined by an 39 
observed pasteurized raw egg challenge and skin prick tests.  40 
Results:  A high proportion (31%) of infants randomized to receive egg (15/49) had an 41 
allergic reaction to the egg powder  and did not continue powder ingestion.  At 4-months of 42 
age, prior to any known egg ingestion, 36% (24/67) infants already had egg-specific IgE 43 
>0.35 kUA/L.  At 12-months, a lower (but not significant) proportion of infants in the egg 44 
group (33%) were diagnosed with IgE-mediated egg allergy compared to the control group 45 
(51%; relative risk 0.65; 95% confidence intervals 0.38 to 1.11; P=0.11). Egg-specific IgG4 46 
levels were significantly (P<0.001) higher in the egg group at both 8 and 12-months.  47 
Conclusion: Induction of immune tolerance pathways and reduction in egg allergy incidence 48 
may be achieved by early regular oral egg exposure in infants with eczema.  Caution needs to 49 
be taken when these high-risk infants are first exposed to egg as many have already 50 
developed sensitization by 4-months of age.   51 
 52 
53 
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Clinical Implications  54 
Caution needs to be taken when infants with moderate to severe eczema are first exposed to 55 
egg as many have already developed sensitization and clinical reactivity by 4-months of age. 56 
 57 
Capsule Summary  58 
Induction of immune tolerance pathways and reduction in egg allergy incidence may be 59 
achieved by early regular oral egg exposure in infants with eczema provided the infant 60 
tolerates their first few exposures to egg. 61 
 62 
Key words 63 
Allergy prevention, complementary feeding, eczema, egg, food allergy, oral tolerance, 64 
randomized controlled trial.  65 
 66 
Abbreviations 67 
CI - confidence intervals  68 
IgE - immunoglobulin E  69 
IgG4 - immunoglobulin G4 70 
ITT - intention to treat 71 
RCT - randomized controlled trial 72 
RR - relative risk 73 
SCORAD - scoring system for atopic dermatitis/eczema  74 
SOTI - specific oral tolerance induction  75 
SPT - skin prick test 76 
77 
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Introduction 78 
Egg allergy is the most common food allergy now affecting 8.9% of children at 1 year of age in 79 
Australia 1.  With rising rates of food allergy 2, there is ongoing confusion and controversy 80 
over the role of allergenic foods in the development of food allergy.  Until recently, it has 81 
been common practice to avoid egg and other allergenic foods for the primary prevention of 82 
food allergy 3.  Although guidelines have been revised to indicate that there is insufficient 83 
evidence to support this 4-7, it is recognized that the level of evidence in this area is generally 84 
weak, based largely on observational studies with methodological limitations and that 85 
randomized control trials are needed to address this more conclusively.  86 
 87 
Animal studies have shown that the development of oral tolerance is driven by regular 88 
allergen exposure and that avoidance strategies may increase the risk of adverse immune 89 
responses to allergens 8.  The potential role of regular food allergen exposure to induce 90 
tolerance in humans is also illustrated by studies of specific oral tolerance induction (SOTI) 91 
in food allergic children 9, 10.  Animal studies have also shown that early exposure to repeated 92 
doses of food proteins (allergens) can induce oral tolerance during a critical early window of 93 
development 8.  While the timing of this potential ‘window’ is not clear in humans, delayed 94 
introduction of specific foods (egg, cow’s milk, fish, oats) beyond 6-9 months of age has 95 
been associated with increased risk of allergic disease in non-intervention cohort studies 11-17.  96 
The Australian Healthnuts study 18 found that delaying introduction of egg until 10-12-97 
months (adjusted OR, 1.6, 95% CI, 1.0-2.6) or after 12-months (adjusted OR 3.4, 95% CI, 98 
1.8-6.5) was associated with significantly higher risk of egg allergy compared with earlier 99 
introduction at 4 to 6 months.  Thus early oral exposure to egg may be an important strategy 100 
to prevent or reduce the risk of developing an egg allergy.  101 
 102 
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Here we report the first randomized controlled trial to investigate whether early introduction 103 
of egg reduces the risk of egg allergy in infants with a history of eczema.  Infantile eczema is 104 
an important risk factor for food allergies 19, and we targeted this population based on their 105 
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Methods 110 
Study design 111 
Singleton, term infants with symptoms of moderate to severe eczema (determined using a 112 
standardized scoring system for atopic dermatitis/eczema [SCORAD] 20 score of ≥15) were 113 
recruited at 4 months of age from two Australian centers (Adelaide and Perth).  Infants who 114 
had commenced solids prior to 4-months of age or who had any previous known direct 115 
ingestion of egg were excluded.  Written informed consent was obtained prior to trial 116 
participation.  Approval was granted by the local Institutional Review Boards (Human 117 
Research Ethics Committees) of each centre, Women’s and Children’s Health Network, 118 
Adelaide and Princess Margaret Hospital, Perth.  The trial was registered with the Australian 119 
New Zealand Clinical Trials Registry: ACTRN12609000415202. 120 
 121 
The study was conducted using a double-blinded randomized controlled trial design. Baseline 122 
characteristics including maternal age at birth, maternal race, Caesarean delivery, smoking in 123 
the household, family (first degree relative) history of allergic disease, infant sex, infant 124 
dietary information on breastfeeding and/or formula feeding, infant history of and treatments 125 
used for eczema were recorded at randomization at 4-months of age.  A blood sample was 126 
collected prior to the first exposure to the study powder.  Baseline egg-specific IgE and IgG4 127 
levels were analyzed at the completion of the trial, and did not influence eligibility. 128 
 129 
Randomization and Blinding 130 
Each participating infant was assigned a unique study number and randomly allocated into 131 
one of two intervention groups.  A computer-generated randomization schedule was produced 132 
by an independent consultant.  The schedule was stratified by infant sex and feeding mode 133 
(breastfed or formula fed if receiving >200ml of infant formula per day) at 4-months of age.  134 
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Independent research assistants coded the identically packaged dietary intervention powders 135 
and these research assistants were not involved in the dietary group allocation or assessment 136 
process, thus keeping the outcome assessments blinded.  137 
 138 
Dietary Intervention 139 
The trial compared the effects of two food powders (egg and rice) in infants’ diets, given 140 
daily from randomization at 4-months of age until 8-months of age.  For both groups the 141 
study powder was given orally by mixing the powder with infant rice cereal.  The 142 
intervention group was allocated to 1 teaspoon (=0.9g egg protein equivalent to 1/6 of an egg) 143 
per day of pasteurized raw whole egg powder manufactured by Farm Pride Foods, 144 
Keysborough, Australia. The control group received 1 teaspoon (=0.25g rice protein) per day 145 
of rice flour powder (ingredients: white rice only) manufactured by Ward McKenzie Pty Ltd, 146 
Altona, Australia.  Rice was chosen as the placebo (control group) as rice cereal is commonly 147 
the first food introduced and IgE-mediated allergic reactions to rice are uncommon.  A 148 
medical assessment, including an observed ingestion of the allocated study powder dose 149 
(were appropriate), was conducted to confirm any possible allergic reactions to the study 150 
powder prior to a decision being made to cease the powder use.  Any infant whose powder 151 
use was ceased was still included in all follow-up assessments.  Infants in both groups were 152 
advised to follow an egg-free diet (with avoidance of egg protein in any food including foods 153 
cooked with egg as an ingredient) from 4 to 8-months of age by an experienced pediatric 154 
dietitian, and to introduce other solid foods based on family diet preferences and the infant’s 155 
individual feeding skill development. 156 
 157 
Infant Allergic Disease Outcome Assessments 158 
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The families were contacted by telephone when the infant was 5, 6, 7 and 10 months of age, 159 
and at 8 and 12-months of age the infant attended a hospital appointment.  At each contact 160 
time point with the families, questions were asked relating to compliance with the dietary 161 
intervention, infant feeding, egg intake, symptoms of allergic disease, doctor visits for 162 
eczema and the use of any treatment medications for eczema.  At the 8 and 12 month 163 
appointments, the infant’s eczema was assessed using SCORAD 20 and a blood sample was 164 
collected to measure whole egg-specific IgE and egg white-specific IgG4 serum antibody 165 
concentrations (see the on-line repository for more details).  166 
 167 
Throughout this trial an allergic reaction was defined as at least 3 concurrent non-contact 168 
urticaria persisting for at least 5 minutes and/or generalised skin erythema (but not an 169 
exacerbation of eczema alone) and/or vomiting (forceful/projectile) and/or anaphylaxis 170 
(evidence of circulatory or respiratory involvement).  A serious adverse event was defined as 171 
any death, admissions to Intensive Care or anaphylactic reaction.  Serious adverse events 172 
were reviewed by a Serious Adverse Event Committee and any such events were reported to 173 
the Human Research Ethics Committees.  174 
 175 
At 8-months of age, all participating infants had a medically supervised cooked egg exposure, 176 
where the infant was given 2 teaspoons of mashed hard-boiled whole egg (equivalent to 1/6 177 
of an egg) to eat and observed for at least 2 hours afterwards.  Unless the infant experienced 178 
an allergic reaction, the families were advised to commence the inclusion of cooked egg 179 
(examples given included hard boiled or fried egg, omelette, quiche, egg in baked goods, egg 180 
in meatballs or egg used for crumbing foods) in the infant’s diet from 8-12-months of age.  181 
 182 
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At 12-months of age, all infants had a medically supervised pasteurized raw egg challenge 183 
where the infant was given ½ whole egg (see the on-line repository for more details) and 184 
observed for at least 2 hours afterwards.  Unless the infant experienced an allergic reaction, 185 
the families were advised to include all forms of egg containing foods in the infant’s diet.  186 
Infants were excluded from the challenge process if they had previous anaphylaxis to egg or 187 
for whom an independent medical decision not to proceed with the egg challenge was made 188 
due to a previous allergic reaction to egg.  On the same day but prior to the egg challenge, the 189 
infants had skin prick tests (SPT) (see the on-line repository for details).  190 
 191 
The primary outcome was the diagnosis of IgE-mediated egg allergy at 12-months of age 192 
defined as an allergic reaction to the pasteurized raw egg challenge and associated evidence 193 
of sensitization to egg or where an independent medical decision not to proceed with the egg 194 
challenge was made due to a previous allergic reaction to egg and associated evidence of 195 
sensitization to egg.   196 
 197 
Statistical analysis 198 
A sample size estimate was calculated based on the assumption that the expected prevalence 199 
of IgE-mediated egg allergy at 12-months of age in a population of infants with eczema 200 
would be 40% 21, so to detect an absolute reduction of 20% (relative reduction of 50%) from 201 
40% to 20% (with 85% power, alpha-value 0.05), we would have required 103 infants per 202 
group. Allowing for 10% loss to follow-up, the aim was to recruit a total of 226 infants into 203 
the trial.  However the study recruitment was paused in September 2011 at the request of the 204 
Human Research Ethics Committee at Princess Margaret Hospital, Perth, to examine the rate 205 
of allergic reactions to the study powder and cases of anaphylaxis. An independent unblinded 206 
Data Safety Monitoring Committee review was undertaken and the recommendation from 207 
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this Committee was that the trial should continue.  The decision was made by the Ethics 208 
Committee to re-open the trial for recruitment in May 2012, however by this time insufficient 209 
funds remained to re-commence recruitment and the Chief Investigators decided the trial 210 
should be terminated early without reaching the sample size originally estimated.  211 
 212 
Analyses were performed according to the intention to treat principle. The proportion of 213 
infants with diagnosed IgE-mediated egg allergy at 12-months of age was compared between 214 
groups. Secondary comparisons between groups included the proportion of children with 215 
cooked egg allergy, eczema severity (objective SCORAD score) and sensitized to egg. 216 
Independent Samples T-Test, Mann-Whitney U, Pearson Chi-Square and Fisher’s Exact Tests 217 
were used to test differences between the groups. Statistical significance was assessed at the 218 
0.05 level. Analyses were performed using SPSS Statistics Software version 20. (IBM, USA).   219 
220 
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Results 221 
Enrolment for the trial began on 15th July, 2009 and ended on 7th September, 2011.  86 222 
infants were randomized into the trial, 49 infants to the egg group and 37 infants to the rice 223 
group. There were no significant differences in the baseline characteristics between the two 224 
groups (Table 1).  Data collection was completed on 25th May 2012.  Ninety percent (77/86) 225 
infants attended their final appointment, with 77/86 (90%) infants having skin prick tests and 226 
67/86 (78%) undertaking an egg challenge. Nine (2 in rice group) parents withdrew their 227 
infant’s consent to participate during the study due to the following reasons: became too busy 228 
to attend hospital appointments (n=4, 1 in rice group), did not like the study powder (n=2, 1 229 
in rice group), infant had repeated illnesses (n=1), family moved overseas (n=1) and parents 230 
did not want to the raw egg challenge (n=1). 231 
 232 
Intervention, compliance and safety  233 
A high proportion (21%) of infants randomized (18/86) had an allergic reaction to their 234 
allocated study powder.  The proportion of reactors was higher (31%) in those allocated to 235 
receive egg (15/49).  Most of these (10/15) had a reaction on the first exposure to the egg 236 
powder, including one case of anaphylaxis.  Three infants in the rice group had allergic 237 
reactions (all had generalized skin erythema and vomiting) to the rice powder, and these 238 
infants were advised to avoid rice in their diet and were followed up for their suspected rice 239 
allergy outside the study by an independent allergist. No participating infants had a positive 240 
SPT to rice at 12 months of age. The trial outcomes of the 18 infants who had allergic 241 
reactions to their allocated study powder are detailed in Table 2.  242 
  243 
For the infants without an allergic reaction to the study powder, compliance with the powder 244 
use was high.  In the egg group 31/33 (94%) infants ingested the study powder at least 4 days 245 
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per week on average during the intervention period, as did 31/32 (97%) infants in the control 246 
group.  Compliance with the egg-free diet intervention from 4-8-months of age did not differ 247 
between the groups; 78% in the egg group compared to 64% in the control group (P=0.15).  248 
Of the 23 infants (10 in the egg group and 13 in the control group) who accidentally ingested 249 
an egg containing food during the intervention period, only one infant (in the egg group) did 250 
so on more than one occasion and only one allergic reaction after ingestion of cake mix 251 
containing raw egg by an infant in the rice group was reported.  The most common egg 252 
containing foods that were accidentally eaten were baked goods (biscuits/cake) (n=12) and 253 
ice cream/custard (n=3). Compliance with the inclusion of cooked egg into the diet of the 254 
infants, who did not react to the cooked egg exposure, from 8-12 months of age was high 255 
with all of these infants (n=63) consuming egg as an ingredient in foods, and 59/63 (94%) 256 
infants consuming whole egg as either quiche, omelette, hard-boiled or scrambled egg.    257 
 258 
Four infants experienced a serious adverse event.  In the egg group, one infant had a hospital 259 
Intensive Care admission with food protein-induced enterocolitis syndrome (FPIES) after a 260 
re-challenge with the study powder to confirm a previous reaction and another had 261 
anaphylaxis on first exposure to the study powder.  In the rice group, two infants had 262 
anaphylaxis, one after the cooked egg exposure and one after the pasteurized raw egg 263 
challenge.  264 
 265 
Clinical outcomes    266 
For the primary outcome, a lower proportion of infants in the egg group (14/42=33%) were 267 
diagnosed with IgE-mediated egg allergy at 12-months of age compared to the control group 268 
(18/35=51%), however the difference did not reach statistical significance (relative risk (RR) 269 
0.65; 95% confidence intervals (CI) 0.38 to 1.11; P=0.11).  Overall 22/67 (33%) of infants 270 
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who had the pasteurized raw egg challenge had an allergic reaction.  Ten infants did not have 271 
a pasteurized raw egg challenge because of an independent medical decision not to proceed 272 
based on a previous documented allergic reaction to egg and associated evidence of 273 
sensitization (positive SPT) to egg.  Secondary outcome analyses found a lower proportion of 274 
infants in the egg group (19/42=45%) were sensitized to egg (positive SPT) at 12-months of 275 
age compared to the control group (22/35=63%), however the difference did not reach 276 
statistical significance (RR 0.72; 95% CI 0.47 to 1.09; P=0.12). There were no differences in 277 
the severity and extent of eczema (objective SCORAD score) at 8-months of age (median in 278 
egg group =7.6, IQR 3.6-14.5; n=42 and median in the control group =7.8, IQR 3.6-14.1, 279 
n=35, P=0.80) or at 12-months of age (median in egg group =7.2, IQR 0.0-12.2; n=42 and 280 
median in the control group =8.2, IQR 0.0-14.4, n=35, P=0.35).  There was also no difference 281 
in the proportion of infants using prescription steroid cream between 4 to 12-months of age 282 
(90% vs 97% in the egg and control groups respectively P=0.37), nor in number of visits to a 283 
doctor for eczema (one visit on average in each group, P=0.75). 284 
 285 
At 8-months of age, the rate of allergic reaction to cooked egg was 16% (12/75); 6/40 (15%) 286 
in the egg group and 6/35 (17%) in the control group (RR 0.88; 95% CI 0.31 to 2.47; 287 
P=0.80).  Eleven infants did not have a cooked egg exposure; 4 due to independent medical 288 
advice after an allergic reaction to the study powder, 1 due to repeated illnesses and 6 289 
withdrawn.  21/22 (95%) infants (6 in egg group and 15 in control group) who reacted to the 290 
pasteurized raw egg challenge were able to tolerate cooked egg prior.   291 
 292 
IgE and IgG4 antibody measurements 293 
There were no differences in baseline egg-specific IgE levels between the groups or at any 294 
other time point (Table 3).  At 4-months of age, prior to any known ingestion of egg, 36% 295 
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(24/67) infants already had egg-specific IgE >0.35 kUA/L.  Within the egg group at 4-months 296 
of age, the egg-specific IgE concentrations were significantly higher (P=0.001) for those 297 
infants who had an allergic reaction to the egg powder (median = 0.78 kUA/L, IQR 0.55-2.07, 298 
n=11) compared to those who tolerated the powder (median = 0.05 kUA/L, IQR 0.05-0.39, 299 
n=24).   300 
 301 
Early ingestion of egg (egg group) was associated with significantly (P<0.001) and 302 
persistently higher egg-specific IgG4 levels (Table 3 and Figure 1).  The median IgE/IgG4 303 
ratio at 12-months of age in the egg group (0.39; IQR 0.05-4.15) was significantly lower 304 
(P=0.001) than the control group (5.14; IQR 1.43-25.28). In  infants with IgE-mediated egg 305 
allergy, the median IgE/IgG4 ratio at 12-months of age (median 15.83; IQR 5.13-65.07) was 306 
significantly higher (P<0.001) than for infants who tolerated the raw egg challenge (median 307 
0.35; IQR 0.05-1.43) (Figure 2). The egg-specific IgE concentrations at 12-months of age in 308 
infants with IgE-mediated egg allergy (median 2.37; IQR 1.23-9.72) were also significantly 309 
higher (P<0.001) than for infants who tolerated the raw egg challenge (median 0.13; IQR 310 
0.05-0.76) (Figure 3).  311 
312 
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Discussion 313 
This is the first reported RCT to investigate the hypothesis that early regular oral exposure to 314 
an allergenic food can  induce oral tolerance and reduce the risk of subsequent food allergy.  315 
We specifically targeted children with moderate to severe eczema in this study because of 316 
their particularly high risk of food allergy.  Recognising that neither the rate of sensitization 317 
nor the rate of clinical reaction has been previously described in this population at this very 318 
young age, we adopted a ‘community scenario’ approach in this study and elected not to pre-319 
test or exclude children on the basis of an egg-specific IgE level at randomisation.  As a result 320 
we observed a high proportion (36%) of infants already sensitized to egg prior to 321 
randomization at 4-months of age and 31% who were allocated to receive egg powder had a 322 
clinical reaction, including one case of anaphylaxis.  This clearly indicates that a high 323 
proportion of young infants with moderate to severe eczema are already sensitized to egg 324 
prior to commencing solid foods (in all cases there was no previous history of known direct 325 
ingestion of egg) through other routes potentially in utero across the placenta, through the 326 
defective skin barrier or through breast milk much earlier than 4-months of age, and 327 
emphasizes the need for caution when first introducing allergenic foods to this high risk 328 
group.  Importantly it is also increasingly clear that the processes leading to food sensitization 329 
are already strongly established by 4-months of age, indicating that much earlier preventive 330 
interventions will ultimately be needed.  Differences in neonatal immune function of 331 
subsequently food allergic children 22, 23 suggest that these events are initiated in utero and 332 
consolidated during the very early postnatal period.  With such a dramatic rise in food allergy 333 
there is a pressing need to define events around much earlier allergen encounter.  334 
 335 
This study was terminated early for logistic reasons (see methods) and we acknowledge that 336 
this is a major limitation due to the resulting insufficient power to show statistically 337 
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significant definitive results.  Even so, the trend for lower incidence of egg allergy in the egg 338 
group (33%) compared to the control group (51%) reduces previous concerns that early 339 
introduction of this allergenic food would be associated with increased egg allergy risk, and 340 
that the data points to the contrary and deserves further study. There are now at least three 341 
other RCTs (Trial Registry details ACTRN 12610000388011, ACTRN 12611000535976, 342 
JPRN-UMIN000008673) investigating early regular egg exposure to reduce the risk of egg 343 
allergy development.  However each of these trials is targeting infants at lower risk of egg 344 
allergy than in the present study.  Our present findings in this very high risk population will 345 
therefore contribute a valuable dimension to the composite picture that will emerge as the 346 
results of each of these trials come to light.   347 
 348 
We chose a particularly allergenic form of egg for the intervention group study powder, 349 
namely pasteurized raw egg, which has equivalent allergenic properties to that of raw egg 24.  350 
The rationale was to induce tolerance to the range of epitopes encountered in the most 351 
allergenic forms of egg, using a powder form that could be easily mixed in with the infant’s 352 
solid foods.  However, this form of egg is also more likely to induce reactions in infants that 353 
are already sensitized.  It is possible that early intervention with cooked or baked egg might 354 
achieve tolerance with less risk of reactivity, although the observational Australian 355 
Healthnuts study 18 suggested that first exposure to more allergenic (unbaked) egg was more 356 
likely to reduce egg allergy risk.  More intervention studies are needed to determine  the best 357 
form to deliver the allergen, although ideally this should be in natural foods. 358 
 359 
Conclusion 360 
Induction of immune tolerance pathways and reduction in the egg allergy rate may be 361 
achieved by early regular oral exposure to egg from 4-months of age in infants with moderate 362 
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to severe eczema.  Caution needs to be taken when these high-risk infants are first exposed to 363 
egg as many have already developed sensitization and clinical reactivity by 4-months of age.  364 
This points to much earlier events in the initiation of food sensitization, well before the 365 
introduction of complementary feeding.  366 
367 
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Table 1: Baseline Characteristics. Values are *mean (standard deviation), . ^ numbers (percentages) or & median (Inter Quartile Range).  452 
  453 
 454 
455 
Characteristic Egg (n=49) Control (n=37) P value 
Maternal age at birth (years) * 32.8 ( 5.5)  32.1 ( 3.4)  0.48 
Maternal Caucasian race ^ 36 (73%) 32 (86%) 0.14 
Caesarian-section birth ^ 17 (35%) 11 (30%) 0.63 
Maternal history of allergic disease ^  37 (76%)  25 (68%)  0.42 
1st degree relative history of allergic disease ^ 44 (90%)  35 (95%)  0.69 
Infant male sex ^  31 (63%)  26 (70%)  0.50 
Age of onset of eczema (months) * 1.8 (1.1)  1.8 (0.9)  0.75 
Eczema severity (objective SCORAD score) & 33.8 (29.2,37.5) 32.7 (25.0,39.5) 0.46 
Use of prescription steroid cream ^ 40 (82%) 28 (76%) 0.50 
Ever breastfed ^ 48 (98%) 37 (100%) 1.00 
Breastfed at randomisation ^ 40 (82%) 31 (84%) 0.96 
Smoking in the household ^ 8 (16%) 3 (8%) 0.34 
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Table 2:  Clinical outcomes of infants (n=18) who had an allergic reaction to the study powder. 456 
Allocated study 
powder 
Doses of study 
powder prior to 
powder use ceased 
Cooked Egg Exposure Pasteurised Raw Egg 
Challenge  
IgE- mediated Egg 
Allergy at 12 months of 
age 
Egg 6 Allergic reaction No challenge Yes 
Egg 3 Tolerated Allergic reaction Yes 
Egg 1 Tolerated Allergic reaction Yes 
Egg 1 No exposure No challenge Yes 
Egg 1 No exposure No challenge Yes 
Egg 5 Allergic reaction No challenge Yes 
Egg 3 Allergic reaction No challenge Yes 
Egg 1 No exposure Withdrawn Unknown (Withdrawn) 
Egg 1 Tolerated Allergic reaction Yes 
Egg 43 Tolerated Tolerated No 
Egg 1 Tolerated Allergic reaction Yes 
Egg 1 Allergic reaction No challenge Yes 
Egg 1 Tolerated Allergic reaction Yes 
Egg 1 No exposure 
(anaphylaxis to study 
powder) 
No challenge (anaphylaxis 
to study powder) 
Yes 
Egg 1 Tolerated Allergic reaction Yes 
Rice 3 Tolerated Allergic reaction Yes 
Rice 7 Allergic reaction 
(anaphylaxis) 
No challenge (anaphylaxis 
to cooked egg exposure) 
Yes 
Rice 3 Allergic reaction No challenge Yes 
 457 
 458 
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Table 3: Egg-specific IgE (kUA/L) and IgG4 (mgA/L) antibody concentrations (median, IQR).  459 
 








    
Egg-specific IgE at 4 months of age  
   0.23 (0.05, 0.78) 
(n=35) 
0.05 (0.05, 0.31) 
(n=31) 
 0.40 
Egg-specific IgE at 8 months of age 0.34 (0.05, 0.86) 
(n=36) 
0.52 (0.05, 3.92) 
(n=23) 
 0.22 
Egg-specific IgE at 12 months of age 0.54 (0.05, 2.55) 
(n=40) 




    
Egg-specific IgG4 at 4 months of age 0.04 (0.04, 0.04) 
(n=35) 
0.04 (0.04, 0.07) 
(n=30) 
 0.23 
Egg-specific IgG4 at 8 months of age 1.00 (0.06, 3.00) 
(n=36) 
0.04 (0.04, 0.04) 
(n=23) 
 <0.001 
Egg-specific IgG4 at 12 months of age 1.76 (0.16, 9.00) 
(n=40) 
0.04 (0.04, 0.74) 
(n=29) 
 <0.001 
     
 Abbreviation: IQR, Inter quartile range.   460 
 461 
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Figure Legends 462 
 463 
Figure 1 : Egg-specific IgG4 (mgA/L) concentrations at 4, 8 and 12-months of age.  464 
 465 
Figure 2: IgE/IgG4 ratio at 12-months of age in infants with IgE-mediated egg allergy 466 
compared to those infants who tolerated the egg challenge. For infants with IgE-mediated 467 
egg allergy, median IgE/IgG4 ratio in the egg group was 15.90 (IQR 4.03-56.86) and in the 468 
control group was 15.75 (IQR 6.42-110.63). For infants who tolerated the egg challenge, the 469 
median IgE/IgG4 ratio in the egg group was 0.09 (IQR 0.02-0.43) and in the control group 470 
was 1.43 (IQR 0.48-1.43). 471 
 472 
Figure 3: Egg-specific IgE concentrations at 12-months of age in infants with IgE-473 
mediated egg allergy compared to those infants who tolerated the egg challenge. For 474 
infants with IgE-mediated egg allergy, the median IgE concentration in the egg group was 475 
2.42 (IQR 1.56-7.50) and in the control group was 2.32 (IQR 1.01-11.40). For infants who 476 
tolerated the egg challenge, the median IgE concentration in the egg group was 0.13 (IQR 477 
0.05-0.84) and in the control group was 0.05 (IQR 0.05-0.60). 478 
 479 
